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Abstract
Immune checkpoint blockade therapies are revolutionizing standard cancer treatments. Immune checkpoint
inhibitors likely function to enhance the tumor specific antigen response in order to achieve favorable clinical
outcomes. Thus, continuous efforts to identify the common tumor-specific antigens are essential for the broad
clinical application of these therapies. Several immunoproteomics approaches have been used in order to screen
for this specificity. In a recent article from Jhaveri and colleagues published in the February issue of Cancer
Immunology Research, antibody biomarkers were screened in pancreatic cancer patients who received allogeneic,
granulocyte-macrophage colony stimulating factor-secreting pancreatic cancer vaccine (GVAX) by using a serum
antibody-based SILAC immunoprecipitation (SASI) approach. Using this assay, several new tumor antigens (MYPT1,
PSMC5 and TRFR) were identified that were found to have significantly different expression in tumors compared
with normal tissue. Moreover, patients with detectable antibodies showed improved disease-free survival after
GVAX therapy. These targets need to be further validated to determine the full spectrum of tumor antigen
immunogencity and their potential clinical application. In addition to antibodies, circulating protein, DNA and RNA
in peripheral blood are under clinical investigation as liquid biopsies and have the potential to provide guidance for
future personalized cancer immunotherapy.
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Background
Immune checkpoint blockade therapies are revolutioniz-
ing standard cancer treatments [1]. It is a paradigm shift
within cancer immunotherapy from a focus on stimulat-
ing the immune system to a focus on releasing the
checkpoint inhibitors resulting in adequate immune and
tumor responses [2]. Tumor rejection antigens allow tu-
mors that are distinct from normal tissue to activate the
immune system and generate robust anti-tumor re-
sponses [3]. Immune checkpoint blockade enhances the
tumor rejection response mediated by these antigens to
achieve favorable clinical outcomes. Therefore, it is of
importance to identify the right tumor rejection antigens
to provide important therapeutic guidance for future
cancer immunotherapy. Novel high-throughput technol-
ogy such as whole exome sequencing allows the systemic
analysis of the mutation load of the tumor as well as the
identification of potentially immunogenic neoantigens [4].
However, the current data illustrate that the majority of
mutated antigens are not shared between patients, and are
instead patient specific [5]. Thus, continuous efforts to
identify common tumor-specific antigens are essential for
the broad clinical application of these therapies.
It is a long standing interest in the potential of anti-
bodies to search for tumor specificity. As Dr. Lloyd J
Old highlighted in his G.H.A Clowes Memorial lecture
three decades ago, “Antibodies might reveal something
specific, something unique about the cancer cell…The
antigenic determinants were recognized by antibody”
[6]. Several immunoproteomics approaches including
Serologic Proteome Analysis (SERPA), Serological ana-
lysis of recombinant cDNA expression libraries (SEREX)
and protein microarrays have been explored extensively
to find tumor associated antigens and their cognate anti-
bodies [7]. SERPA is a robust immunoproteomics assay
to screen antibody reactivity profiles in sera from pa-
tients with various diseases. SEREX is another approach
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to assess the antibody profile in patient sera by using
proteins employed on a membrane. NY-ESO-1 was the
first cancer testis antigen discovered by SEREX technol-
ogy. The application of SERPA and SEREX technologies
is relatively limited due to the assay specificity and the
complexity of the assay preparation and procedure. In
addition, the proteins on SEREX membrane expressed
by tumor cDNA phase library in bacterial do not ac-
count for human posttranslational modification.
Protein microarrays are based upon the development
of DNA microarray techniques and have thousands of
purified proteins immobilized on a solid surface. Protein
microarrays are generally classified into three types: ana-
lytical, functional and reverse-phase protein microarrays.
ProtoArray®, a functional array, offers a unique approach
to analyze the serological response against thousands of
protein at the same time. This approach is limited by the
number of proteins coated on the slides (e.g., not all hu-
man proteins are present, and mutated or modified ver-
sions of proteins may not be available) [7].
Main text
In the February issue of Cancer Immunology Research
[8], Jhaveri and colleagues used quantitative seroproteo-
mics to identify antibody biomarkers in pancreatic
cancer patients treated with allogeneic, granulocyte-
macrophage colony stimulating factor-secreting pancre-
atic cancer vaccine (GVAX). The authors took advantage
of stable, isotope-labeled amino acids (SILAC) in
pancreatic ductal adenocarcinoma cell culture, im-
mune precipitation with patient-derived antibodies
and mass spectrometric analysis. They developed a
serum antibodies-based SILAC immuneprecipitation
(SASI) approach to identify antibody response elicited
by the vaccination.
In this study, pre-vaccine sera was intentionally sub-
tracted from post-vaccine sera in order to assess the
vaccine-induced specific antibody responses. In doing
so, a few antibodies were identified as targets from post-
vaccination samples in patients with favorable clinical
outcome. The expression of three antigens (MYPT1,
PSMC5 and TRFR) was measured in tumor and normal
duct epithelium, and significant differences were found
in the expression of these three antigens in tumor com-
pared with normal tissue. Moreover, patients with de-
tectable identified antibodies showed improved disease-
free survival.
Overall, the SASI approach was found to identify new
tumor antigens as potential biomarkers and therapeutic
targets. This approach could also be applied to other
similar clinical studies without protein synthesis, but
these new targets require further validation as possible
pancreatic cancer biomarkers. The caveat and potential
limitation of this study is the subtraction of pre-vaccine
sera. It limits the ability to identify the baseline antibody
response, which may predict the patient’s response to
GVAX vaccination. In addition, allogeneic tumor cells
instead of autologous tumor cell lines were used for the
vaccination. Thus, targets from autologous tumor cells
may be partially missed because of the limitation of the
allogeneic tumor immunogenicity profile.
Perspective and future directions
The SASI approach is an effective method to identify
tumor-specific antigens, especially common tumor rejec-
tion antigens that would allow for the development of
“off-the-shelf” vaccinations. In addition to the validation
of the expression and distribution of these new targets,
it is of importance to further characterize these anti-
bodies and the antigen-specific CD4+ and CD8+ T cell
response. The dissociation between antibody responses
and antigen-specific CD8+ T-cell responses is frequently
observed with other tumor antigens. CTLA-4 blockade
induced a broad antibody response in cancer patients
with ovarian, prostate cancer and melanoma [9, 10]. Ad-
vanced melanoma patients with integrated immune re-
sponses to NY-ESO-1 antigen had a favorable clinical
course after ipilimumab treatment [11]. The majority of
NY-ESO-1 seropositive patients without detectable NY-
ESO-1–specific CD8+ T cells did not experience clinical
benefit. Therefore, cellular tumor antigen-specific CD4+
and CD8+ T cell response needs to be evaluated to ob-
tain the full spectrum of the identified antigens immu-
nogencity and explore the potential clinical application.
Antibodies are useful for the discovery of tumor-
specific antigens. Moreover, antibodies may be able to
directly or indirectly eliminate tumor cells through
opsonization, antigen presentation to T cells and by ini-
tiating NK cells or complement-dependent cell toxicity
[12]. Several potential clinical applications of antibodies
including antibody-drug conjugates, antibody cytokine
fusions and bispecific/multispecific antibodies are under
clinical investigation. A low success rate of current
monoclonal antibody therapy is likely due to low sensi-
tivity and specificity. Sensitivity and specificity of the tar-
get is critical for successful application [13].
In addition to antibodies, proteins circulating in blood
could be potential biomarkers for cancer immunother-
apy. As an example, patients with low baseline vascular
endothelial growth factor (VEGF) experienced better
clinical outcome in advanced melanoma patients treated
with ipilimumab. Thus, serum VEGF may be a predictive
biomarker for ipilimumab treatment [14]. With advances
in mass spectrometry-based serum assays, automated
database search algorithms and the proteome discoverer
software platform, a mass spectrometry-based serum
assay was recently developed to predict clinical outcome
in patients treated with PD-1 blockade [15]. Fifty-nine
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mass spectral (MS) selected from 351 MS identified
from the results of baseline serum were defined as
DBX008+ and DBX008-. Patients with DBX008+ have a
better time to tumor progression and overall survival
than patients with DBX008-. Similar to VEGF, these MS
themselves in the peripheral blood may have immuno-
modulatory impacts on human immune cells. The
amount of these MS may also be associated with im-
mune suppression or activation in tumor microenviron-
ment. Further characterization of these MS will provide
additional information to understand mechanism of ac-
tion in these patients treated with immune checkpoint
blockade.
Besides proteins and antibodies, tumor cells can also
release DNA and RNA into the blood by a variety of
microvesicle-dependent or -independent mechanisms.
Novel technologies with minimal specimen requirements
allow the characterization of these tumor derived DNA
and RNA. Liquid biopsies including cell-free circulating
tumor DNA (ctDNA) from plasma have been investi-
gated for non-invasive detection and monitoring of pa-
tient tumors as well as potential biomarkers for cancer
immunotherapies [16, 17]. The validation of these assays
focused on the serial analyses of DNA, RNA and pro-
tein/antibody in peripheral blood will allow us to identify
changes in the tumor in real time, detect tumor
response or relapse early, identify potential pharmacody-
namic/pharmacokinetic predictive biomarkers related to
the treatment, understand the resistance mechanisms
and provide guidance for future monotherapy or combin-
ation personalized cancer immunotherapy.
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